These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 33915501)

  • 21. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
    Singh YP; Kumar N; Chauhan BS; Garg P
    Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrine derivatives and Alzheimer's disease.
    Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
    Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease.
    Orhan IE
    Curr Med Chem; 2012; 19(14):2252-61. PubMed ID: 22414107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment.
    Pinho BR; Ferreres F; Valentão P; Andrade PB
    J Pharm Pharmacol; 2013 Dec; 65(12):1681-700. PubMed ID: 24236980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
    Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
    Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural Peptides in Drug Discovery Targeting Acetylcholinesterase.
    Prasasty V; Radifar M; Istyastono E
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30217053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
    Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacology of Alzheimer's disease: where do we go from here?].
    Sellal F; Nieoullon A; Michel G; Michel BF; Lacomblez L; Geerts H; Delini-Stula A; Bentué-Ferrer D; Bordet R; Allain H
    Therapie; 2005; 60(2):89-107. PubMed ID: 15969312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of anti-Alzheimer's disease drug based on beta-amyloid hypothesis].
    Sugimoto H
    Yakugaku Zasshi; 2010 Apr; 130(4):521-6. PubMed ID: 20371996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
    Rees TM; Brimijoin S
    Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
    Fisher A
    Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.